A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase Ia Study in Healthy Adult Subjects to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of SYHA1805
Latest Information Update: 07 Jun 2022
At a glance
- Drugs SYHA-1805 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 26 Aug 2021 According to a CSPC Pharmaceutical Group media release, the company obtained clinical trial approval in China for SYHA1805 tablets.
- 01 Dec 2020 New trial record